412 results match your criteria oral fosfomycin

Activity of Fosfomycin and Nitrofurantoin Against Contemporary Pathogens Isolated from Indian Tertiary Care Hospitals.

Microb Drug Resist 2021 May 13;27(5):678-684. Epub 2020 Oct 13.

Wockhardt Research Centre, D4 MIDC, Aurangabad, India.

In India, multidrug resistance in community and hospital associated Gram-negative pathogens has increased sharply over the past few years. In the absence of novel oral multidrug resistant-pathogen active therapies, the therapeutic situation with regard to community infections is even more challenging. Hence, the focus is now shifting toward potentially expanding the utility of older antibiotics such as fosfomycin and nitrofurantoin beyond their approved pathogen coverage. Read More

View Article and Full-Text PDF

IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis.

J Antimicrob Chemother 2021 Apr 14. Epub 2021 Apr 14.

Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK.

Background: Fosfomycin has the potential to be re-purposed as part of a combination therapy to treat neonatal sepsis where resistance to current standard of care (SOC) is common. Limited data exist on neonatal fosfomycin pharmacokinetics and estimates of bioavailability and CSF/plasma ratio in this vulnerable population are lacking.

Objectives: To generate data informing the appropriate dosing of IV and oral fosfomycin in neonates using a population pharmacokinetic analysis of plasma and CSF data. Read More

View Article and Full-Text PDF

Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials.

Open Forum Infect Dis 2021 Mar 2;8(3):ofab045. Epub 2021 Feb 2.

GST Micro LLC, Richmond, Virginia, USA.

Background: For new antibiotics developed to treat antibiotic-resistant Gram-negative infections, the US Food and Drug Administration (FDA) regulatory pathway includes complicated urinary tract infection (cUTI) clinical trials in which the clinical isolates are susceptible to the active control. This allows for inferential testing in a noninferiority study design. Although complying with regulatory guidelines, individual clinical trials may differ substantially in design and patient population. Read More

View Article and Full-Text PDF

Potential interactions between an oral fosfomycin formulation and feed or drinking water: Impact on bioavailability in piglets.

J Vet Pharmacol Ther 2021 Mar 15. Epub 2021 Mar 15.

Área Toxicología, Departamento de Fisiopatología, Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires, Tandil, Argentina.

Feed and drinking water are the most frequently used vehicles for administration of antibiotics in intensive pig production. Interactions of drugs with feed and water components may affect dissolution and bioavailability. Therefore, antibiotic formulations should be tested in order to assure their suitability for oral use. Read More

View Article and Full-Text PDF

Uropathogens antibiotic susceptibility as an indicator for the empirical therapy used for urinary tract infections: a retrospective observational study.

Iran J Microbiol 2020 Oct;12(5):395-403

Department of Pharmacy, Al-Fayhaa Teaching Hospital, Basrah, Iraq.

Background And Objectives: Urinary tract infection (UTI) is a common infection affects people of different ages. It is important to explore the antibiotics susceptibility of the bacterial agents to improve the empirical antibacterial prescription because of emerging of multi-drug resistant (MDR) bacteria.

Materials And Methods: This is a retrospective observational study including 322 patients with UTI at the largest hospital at the center of Al-Basrah Governorate in the far south of Iraq from August 2018 to November 2019. Read More

View Article and Full-Text PDF
October 2020

Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients: Results from a Spanish multicenter cohort.

Antimicrob Agents Chemother 2021 Feb 8. Epub 2021 Feb 8.

Department of Infectious Diseases, Hospital del Mar, Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Barcelona, Spain.

Current guidelines recommend against systematic screening or treating asymptomatic bacteriuria (AB) among kidney transplant (KT) recipients, although the evidence regarding episodes occurring early after transplantation or in the presence of anatomical abnormalities is inconclusive. Oral fosfomycin may constitute a good option for the treatment of post-transplant AB, particularly due to the emergence of multidrug-resistant (MDR) uropathogens. Available clinical evidence supporting its use in this specific setting, however, remains scarce. Read More

View Article and Full-Text PDF
February 2021

In vitro and in vivo antibacterial activity of nitrofurantoin against clinical isolates of E. coli in Japan and evaluation of biological cost of nitrofurantoin resistant strains using a mouse urinary tract infection model.

J Infect Chemother 2021 Feb 12;27(2):250-255. Epub 2020 Oct 12.

Department of Clinical Infectious Diseases, Aichi Medical University Graduate School of Medicine, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.

Introduction: Nitrofurantoin is a well-established antibiotic, and is an important first-line oral treatment for uncomplicated urinary tract infections. However, little information is available with respect to its antibacterial activity in Japan, in vivo efficacy, or the in vivo biological cost of resistant strains.

Methods: We compared the susceptibility of six representative antibacterial agents-nitrofurantoin, sulfamethoxazole/trimethoprim, fosfomycin, mecillinam, ciprofloxacin, and cefdinir-against E. Read More

View Article and Full-Text PDF
February 2021

Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.

Am J Health Syst Pharm 2020 Nov;77(Supplement_4):S105-S110

Department of Pharmacy, Mease Countryside Hospital, Safety Harbor, FL.

Purpose: A protocol was started within a large health system to automatically test all confirmed extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli urine isolates for susceptibility to fosfomycin, an antibiotic not routinely included in such testing in most institutions. This study assessed the effectiveness of the protocol at reducing carbapenem use for the definitive treatment of ESBL E. coli urinary tract infection (UTI) through several endpoints. Read More

View Article and Full-Text PDF
November 2020

Effective Treatment for Uncomplicated Urinary Tract Infections with Oral Fosfomycin, Single Center Four Year Retrospective Study.

Antibiotics (Basel) 2020 Aug 13;9(8). Epub 2020 Aug 13.

Institute of Clinical Microbiology, University Hospital, Sokolska 581, 500 05 Hradec Kralove, Czech Republic.

Fosfomycin represents a relatively old antibiotic, but it is experiencing a comeback in recent years. According to some studies, the increasing therapeutic use of this drug led to a rapid increase in the levels of resistance in bacteria causing urinary tract infection. In the presented study, levels of resistance to fosfomycin in more than 3500 bacterial isolates before and after fosfomycin introduction into therapeutic use in the Czech Republic and the clinical efficacy of treatment in 300 patients using this drug were assessed. Read More

View Article and Full-Text PDF

Potential Allylpyrocatechol Derivatives as Antibacterial Agent Against Oral Pathogen of ATCC 10,556 and as Inhibitor of MurA Enzymes: in vitro and in silico Study.

Drug Des Devel Ther 2020 27;14:2977-2985. Epub 2020 Jul 27.

Department of Oral Biology, Faculty of Dentistry, Universitas Padjadjaran, Bandung, Indonesia.

Background: is Gram-positive bacteria that contribute to caries. Many antibacterial agents are resistant against bacteria so that the discovery of new antibacterial agents is a crucial issue. Mechanism of antibacterial agents by disrupting cell wall bacteria is a promising target to be developed. Read More

View Article and Full-Text PDF

Pharmacotherapeutic advances for recurrent urinary tract infections in women.

Expert Opin Pharmacother 2020 Nov 27;21(16):2011-2026. Epub 2020 Jul 27.

2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens , Athens, Greece.

Introduction: Treatment of recurrent Urinary tract infections (UTIs) has become challenging because of the dramatic increase in the rates of recurrent infection andof multidrug-resistant (MDR) infections.

Areas Covered: The authors review recurrent UTIs(rUTI) management in women.

Expert Opinion: Continuous or post-coital prophylaxis with low-dose antimicrobials or intermittent self-treatment has all been demonstrated to be effective in managing rUTIs in women. Read More

View Article and Full-Text PDF
November 2020

Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection.

J Antimicrob Chemother 2020 11;75(11):3278-3285

Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands.

Objectives: To evaluate the pharmacokinetics and clinical effectiveness of IV and oral fosfomycin treatment in patients with recurrent urinary tract infection (rUTI) with Escherichia coli.

Patients And Methods: Patients with rUTI treated with 3 g of oral fosfomycin every 72 h for at least 14 days were included in a prospective open-label single-centre study. Serum samples were taken after oral and IV administration of fosfomycin. Read More

View Article and Full-Text PDF
November 2020

Potential Fatty Acid as Antibacterial Agent Against Oral Bacteria of Streptococcus mutans and Streptococcus sanguinis from Basil (Ocimum americanum): In vitro and In silico Studies.

Curr Drug Discov Technol 2021 ;18(4):532-541

Department of Chemistry, Faculty of Mathematics and Natural Science, Universitas Padjadjaran, Sumedang, Indonesia.

Background: Streptococcus mutans and Streptococcus sanguinis are Gram-positive bacteria that cause dental caries. MurA enzyme acts as a catalyst in the formation of peptidoglycan in bacterial cell walls, making it ideal as an antibacterial target. Basil (Ocimum americanum) is an edible plant that is diverse and has been used as a herbal medicine for a long time. Read More

View Article and Full-Text PDF
January 2021

Potential of MurA Enzyme and GBAP in Fsr Quorum Sensing System as Antibacterial Drugs Target: In vitro and In silico Study of Antibacterial Compounds from Myrmecodia pendans.

Comb Chem High Throughput Screen 2021 ;24(1):109-118

Department of Chemistry, Faculty of Mathematics and Natural Science, Universitas Padjadjaran, Sumedang, Indonesia.

Background: Increasing the resistance issue has become the reason for the development of new antibacterial in crucial condition. Many ways are tracked to determine the most effective antibacterial agent. Some proteins that are a key role in bacteria metabolism are targeted, including MurA in cell wall biosynthesis and gelatinase biosynthesis-activating pheromone (GBAP) in Fsr Quorum Sensing (QS) system. Read More

View Article and Full-Text PDF
January 2021

Management of Chronic Bacterial Prostatitis.

Curr Urol Rep 2020 Jun 3;21(7):29. Epub 2020 Jun 3.

The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, 4940 Eastern Avenue, 301 Building, Suite 3112, Baltimore, MD, 21224, USA.

Purpose Of Review: We conducted a review of the literature describing the most up-to-date diagnosis and treatment options of chronic bacterial prostatitis.

Recent Findings: Recurrence after oral antimicrobial therapy is common, due in part to the rising rates of antimicrobial resistance and inability to completely clear the offending bacteria from the prostate following prostatitis. Recent literature has described various treatment options for chronic bacterial prostatitis refractory to conventional antimicrobial agents, including the use of alternative agents such as fosfomycin, direct antimicrobial injections into the prostate, surgical removal of infected prostatic tissue, chronic oral antibiotic suppression, and an emerging novel therapy utilizing bacteriophages to target antibiotic resistant bacteria. Read More

View Article and Full-Text PDF

A comparison of different antibiotic regimens for the treatment of infective endocarditis.

Cochrane Database Syst Rev 2020 05 14;5:CD009880. Epub 2020 May 14.

Department of Family Medicine, Northwell Health Southside Hospital, Bay Shore, New York, USA.

Background: Infective endocarditis is a microbial infection of the endocardial surface of the heart. Antibiotics are the cornerstone of treatment, but due to the differences in presentation, populations affected, and the wide variety of micro-organisms that can be responsible, their use is not standardised. This is an update of a review previously published in 2016. Read More

View Article and Full-Text PDF

Efficacy of food supplement Acidif plus® in the treatment of uncomplicated UTIs in women: a pilot observational study.

Minerva Ginecol 2020 Apr;72(2):70-74

ASL NA3 SUD, Naples, Italy.

Background: Urinary tract infections (UTIs) are among the most common bacterial infection diagnosed in women. The standard therapy is represented by short course of anti-microbial treatment to eradicate causative pathogens. However, due to antibiotic treatment, normal microbiota of the gastrointestinal tract is at risk of depletion and prolonged use of antibiotics can lead to the development of resistant strains. Read More

View Article and Full-Text PDF

Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.

J Antimicrob Chemother 2020 07;75(7):1879-1888

Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia.

Objectives: We used a dynamic bladder infection in vitro model with synthetic human urine (SHU) to examine fosfomycin exposures to effectively kill, or prevent emergence of resistance, among Pseudomonas aeruginosa isolates.

Methods: Dynamic urinary fosfomycin concentrations after 3 g oral fosfomycin were simulated, comparing single and multiple (daily for 7 days) doses. Pharmacodynamic response of 16 P. Read More

View Article and Full-Text PDF

Chronic high-level multidrug-resistant Campylobacter coli enterocolitis in an agammaglobulinemia patient: Oral gentamicin efficacy.

M Dan M Parizade

Med Mal Infect 2020 Sep 27;50(6):525-527. Epub 2020 Apr 27.

Maccabi Health Services, Bacteriology Unit, National Laboratory, Rehovot, Israel.

Background: Campylobacter is the most common cause of infectious diarrhea in agammaglobulinemia patients. These infections can be severe, prolonged, and recurrent in such patients.

Patient And Methods: We report a 29-year-old male patient with X-linked agammaglobulinemia with Campylobacter coli enterocolitis that persisted for nine months despite multiple 10- to 14-day courses of oral ciprofloxacin and azithromycin. Read More

View Article and Full-Text PDF
September 2020

Susceptibility pattern of oral antimicrobials in uncomplicated UTI: Does fosfomycin still stand effective?

J Family Med Prim Care 2020 Feb 28;9(2):850-853. Epub 2020 Feb 28.

Department of Lab Medicine, All India Institute of Medical Sciences, New Delhi, India.

Introduction: Urinary tract infections (UTIs) are a leading cause of morbidity amongst all age groups and most patients with uncomplicated UTI who visit the OPD are treated with empirical antibiotics without doing any culture analysis. Of all the oral antibiotics used in UTI, fosfomycin is well excreted in the urine and is being used for the treatment of UTIs with a single oral dose.

Methodology: The current study was planned to determine the resistance amongst uropathogens to various oral antibiotics including fosfomycin isolated over a 4-year period (April 2015 to March 2019). Read More

View Article and Full-Text PDF
February 2020

Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system.

J Antimicrob Chemother 2020 07;75(7):1993-1997

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.

Background: The rising incidence of MDR uropathogens has driven increased use of oral fosfomycin for treatment of complicated urinary tract infections (cUTIs). However, there are limited data to support its use for cUTI, especially pyelonephritis.

Methods: We performed a retrospective review of all oral fosfomycin prescriptions between 1 January and 31 December 2017 in the Los Angeles County Department of Health Service system, the second largest US municipal health system. Read More

View Article and Full-Text PDF

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections.

Can J Infect Dis Med Microbiol 2020 28;2020:8513405. Epub 2020 Mar 28.

Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

Oral fosfomycin is approved in Canada for the treatment of acute uncomplicated cystitis. Several studies have reported "off label" use of oral fosfomycin in the treatment of patients with complicated lower urinary tract infection (cLUTI). This review summarizes the available literature describing the use of oral fosfomycin in the treatment of patients with cLUTI. Read More

View Article and Full-Text PDF

Potential of fosfomycin in treating multidrug-resistant infections in children.

J Paediatr Child Health 2020 Jun 15;56(6):864-872. Epub 2020 Apr 15.

Department of Infectious Diseases and Immunology, Sydney Children's Hospital, Sydney, New South Wales, Australia.

In an era of increasing antimicrobial resistance, there are limited treatment options available to treat multidrug-resistant organisms in paediatric patients. Fosfomycin is an antibiotic defined as 'critically important' by The World Health Organization due to its potential efficacy against multidrug-resistant bacteria and is increasingly cited in the international literature as a promising antimicrobial for combating sepsis in an era of increasing antimicrobial resistance. With broad-spectrum cover that includes both Gram-positive and Gram-negative organisms and both parenteral and oral formulations available, fosfomycin provides a promising treatment option for paediatric patients. Read More

View Article and Full-Text PDF

Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic Model.

Antimicrob Agents Chemother 2020 05 21;64(6). Epub 2020 May 21.

Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia

There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undertook pharmacodynamic profiling of fosfomycin against and isolates using a dynamic bladder infection model. Read More

View Article and Full-Text PDF

Etiology and bacterial susceptibility to antibiotics in patients with recurrent lower urinary tract infections.

Pol Arch Intern Med 2020 05 6;130(5):373-381. Epub 2020 Apr 6.

Department of Internal Medicine and Transplant Nephrology, Medical University of Lodz, Łódź, Poland.

Introduction: Recurrent urinary tract infections (UTIs) are a frequent health problem and a common reason for treatment resistance.

Objectives: The purpose of the study was to evaluate the etiology of community‑ acquired lower recurrent UTI and bacterial antibiotic susceptibility.

Patients And Methods: A total of 796 microbiological urine cultures from 332 patients (280 women and 52 men) treated in a single nephrology outpatient department in central Poland in years 2016 to 2018 were analyzed. Read More

View Article and Full-Text PDF

The effect of antibiotics on the gut microbiome: a metagenomics analysis of microbial shift and gut antibiotic resistance in antibiotic treated mice.

BMC Genomics 2020 Mar 30;21(1):263. Epub 2020 Mar 30.

U. S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Science, Office of Clinical Pharmacology, Division of Applied Regulatory Science, HFD-910, White Oak Federal Research Center, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA.

Background: Emergence of antibiotic resistance is a global public health concern. The relationships between antibiotic use, the gut community composition, normal physiology and metabolism, and individual and public health are still being defined. Shifts in composition of bacteria, antibiotic resistance genes (ARGs) and mobile genetic elements (MGEs) after antibiotic treatment are not well-understood. Read More

View Article and Full-Text PDF

Antibiotic prophylaxis for transrectal ultrasound-guided prostate needle biopsy: Compared efficacy of ciprofloxacin vs. the ciprofloxacin/fosfomycin tromethamine combination.

Can Urol Assoc J 2020 Aug;14(8):267-272

Urology Service UroLaval, Cité-de-la-Santé Hospital, Laval and St-Eustache Hospital, affiliated with Université de Montréal, Montreal, QC, Canada.

Introduction: Some authors advocate an increase in post-prostate needle biopsy (PNB) infections associated with emergent quinolone resistance in E. coli, urging re-evaluation of antibiotic prophylaxis (antibioprophylaxis). In this study, we compared rates of post-PNB urosepsis associated with two oral regimens of antibioprophylaxis: ciprofloxacin (CIP) vs. Read More

View Article and Full-Text PDF

[Current state of antibiotic resistance of pathogens causing community-acquired urinary tract infections in Russia, Belarus and Kazakhstan: results of the international multicenter study Darmis-2018].

Urologiia 2020 Mar(1):19-31

Smolensk State Medical University, Smolensk, Russia.

Objective: To study in vitro activity of antimicrobials against clinical isolates from patients with community-acquired urinary tract infections (UTIs) in different regions of Russia, Belarus and Kazakhstan in 2017-2018.

Materials And Methods: A total of 1260 isolates collectedin the Russian Federation, Belarus and Kazakhstanas a part of the international multicenter prospective epidemiological study of the dynamics of antimicrobial resistance of uropathogens causing community-acquired urinary tract infections in different subsets of patients ("DARMIS-2018") were included in the analysis. 1124 strains represented the Enterobacterales order. Read More

View Article and Full-Text PDF

Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study.

Int J Antimicrob Agents 2020 Jul 8;56(1):105935. Epub 2020 Mar 8.

Department of Urology, Oslo University Hospital, Oslo, Norway and Institute of Clinical Medicine, University of Oslo, Norway and Institute of Clinical Medicine, University of Aarhus, Denmark.

This paper presents the results of a pilot study of difficult-to-treat patients (exhibiting several previous treatment failures or detection of extended-spectrum beta-lactamase [ESBL] strains) with chronic bacterial prostatitis (CBP) who underwent treatment with fosfomycin trometamol (FT) and N-acetyl-L-cysteine (NAC). Twenty-eight patients with clinically- and microbiologically-confirmed CBP who attended a single urological institution between January 2018 and March 2019 were treated with oral administration of 3 g FT once a day for 2 days, followed by a dose of 3 g every 48 h for 2 weeks, in combination with oral administration of NAC 600 mg once a day for 2 weeks. Clinical and microbiological analyses were carried out at the time of admission (T0) and during follow-up at 1 month (T1) and 6 months (T2) after the end of treatment. Read More

View Article and Full-Text PDF

Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting.

Open Forum Infect Dis 2020 Feb 29;7(2):ofaa034. Epub 2020 Jan 29.

Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.

Background: Few published studies exist to describe the off-label use of multiple-dose fosfomycin for outpatient treatment of complicated urinary tract infections (UTI). The purpose of this study was to characterize the patients, infections, drug susceptibilities, and outcomes of multiple-dose fosfomycin episodes for outpatient UTI treatment.

Methods: This retrospective study evaluated patients who received an outpatient prescription for multiple-dose fosfomycin between July 1999 and June 2018. Read More

View Article and Full-Text PDF
February 2020